LETTER Doi:10.1038/Nature09515

Total Page:16

File Type:pdf, Size:1020Kb

LETTER Doi:10.1038/Nature09515 LETTER doi:10.1038/nature09515 Distant metastasis occurs late during the genetic evolution of pancreatic cancer Shinichi Yachida1*, Siaˆn Jones2*, Ivana Bozic3, Tibor Antal3,4, Rebecca Leary2, Baojin Fu1, Mihoko Kamiyama1, Ralph H. Hruban1,5, James R. Eshleman1, Martin A. Nowak3, Victor E. Velculescu2, Kenneth W. Kinzler2, Bert Vogelstein2 & Christine A. Iacobuzio-Donahue1,5,6 Metastasis, the dissemination and growth of neoplastic cells in an were present in the primary pancreatic tumours from which the meta- organ distinct from that in which they originated1,2, is the most stases arose. A small number of these samples of interest were cell lines common cause of death in cancer patients. This is particularly true or xenografts, similar to the index lesions, whereas the majority were for pancreatic cancers, where most patients are diagnosed with fresh-frozen tissues that contained admixed neoplastic, stromal, metastatic disease and few show a sustained response to chemo- inflammatory, endothelial and normal epithelial cells (Fig. 1a). Each therapy or radiation therapy3. Whether the dismal prognosis of tissue sample was therefore microdissected to minimize contaminat- patients with pancreatic cancer compared to patients with other ing non-neoplastic elements before purifying DNA. types of cancer is a result of late diagnosis or early dissemination of Two categories of mutations were identified (Fig. 1b). The first and disease to distant organs is not known. Here we rely on data gen- largest category corresponded to those mutations present in all samples erated by sequencing the genomes of seven pancreatic cancer meta- from a given patient (‘founder’ mutations, mean of 64%, range 48–83% stases to evaluate the clonal relationships among primary and of all mutations per patient; Fig. 1b, example in Supplementary Fig. 2a). metastatic cancers. We find that clonal populations that give rise These data indicate that the majority of somatically acquired mutations to distant metastases are represented within the primary carcin- present in pancreatic cancers occur before the development of meta- oma, but these clones are genetically evolved from the original static lesions. All other mutations were characterized as ‘progressor’ parental, non-metastatic clone. Thus, genetic heterogeneity of mutations (mean of 36%, range 17–52% of all mutations per patient; metastases reflects that within the primary carcinoma. A quanti- tative analysis of the timing of the genetic evolution of pancreatic cancer was performed, indicating at least a decade between the a Pancreas Peritoneum Liver Lung occurrence of the initiating mutation and the birth of the parental, non-metastatic founder cell. At least five more years are required for the acquisition of metastatic ability and patients die an average of two years thereafter. These data provide novel insights into the genetic features underlying pancreatic cancer progression and define a broad time window of opportunity for early detection to prevent deaths from metastatic disease. b 90 We performed rapid autopsies of seven individuals with end stage Progressor pancreatic cancer (Supplementary Table 1). In all patients, metastatic 80 Founder deposits were present within two or more anatomic sites in each 70 patient, most often the liver, lung and peritoneum, as is typical for this form of neoplasia4. 60 Low passage cell lines (six patients) or first passage xenografts (one 50 patient) were created from one of the metastases present at each 40 patient’s autopsy. These samples comprised seven of the 24 pancreatic cancers which previously underwent whole exome sequencing and mutations Total 30 copy number analysis, as described in a mutational survey of the 20 5 pancreatic cancer genome . In this earlier study, a total of 426 somatic 10 mutations in 388 different genes were identified among 220,884,033 0 base pairs (bp) sequenced in the seven index metastatic lesions, cor- Pa01 Pa02 Pa03 Pa04 Pa05 Pa07 Pa08 responding to an average of 61 mutations per index metastatic lesion (range 41–77). In all samples, the vast majority of mutations were Figure 1 | Summary of somatic mutations in metastatic pancreatic cancers. represented by missense or silent single base substitutions (Sup- a, Histopathology of primary infiltrating pancreatic cancer and metastatic pancreatic cancer to the peritoneum, liver and lung. In addition to infiltrating plementary Fig. 1 and Supplementary Table 2). cancer cells in each lesion (arrows), non-neoplastic cell types are abundant. For each of the somatic mutations identified in the seven index b, Total mutations representing parental clones (founder mutations), and metastasis lesions, we determined whether the same somatic mutation clonal evolution (progressor mutations) within the primary carcinoma based was present in anatomically distinct metastases harvested at autopsy on comparative lesion sequencing. Mutations common to all samples analysed from the same patients. We also determined whether these mutations were the most common category identified. 1Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA. 2The Ludwig Center for Cancer Genetics and Therapeutics and The Howard Hughes Medical Institute at The Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland 21231, USA. 3Program for Evolutionary Dynamics, Department of Mathematics, Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, Massachusetts 02138, USA. 4School of Mathematics, University of Edinburgh, Edinburgh EH9 3JZ, UK. 5Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA. 6Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA. *These authors contributed equally to this work. 1114 | NATURE | VOL 467 | 28 OCTOBER 2010 ©2010 Macmillan Publishers Limited. All rights reserved LETTER RESEARCH Fig. 1b, example in Supplementary Fig. 2b). These mutations were upon which were superimposed an accumulation of progressor muta- present in one or more of the metastases examined, including the index tions associated with clonal evolution and metastasis. metastasis, but not the parental clone. Evolutionary maps were constructed for each patient’s carcinoma These mutation types were used to classify the lesions that contained based on the patterns of somatic mutation and allelic losses and the them into parental clones (containing only founder mutations) and locations of individual metastatic deposits (Fig. 2 and Supplementary subclones (containing both founder and progressor mutations). By Figs 3–8). These maps showed that, despite the presence of numerous definition, there could be only one parental clone in a patient, although founder mutations within the parental clones, the cells giving rise to there could be many different subclones. Parental clones tended to the metastatic lesions had a large number of progressor mutations. For contain more deleterious mutations (nonsense, splice site or frameshift example, in Pa01 the parental clone contained 49 founder mutations, mutations) than subclones (12.6% of the mutations in the parental yet a clonal expansion marked by the presence of mutations in six clones versus 8.1% of the mutations in subclones, Supplementary additional genes was present in the lung and peritoneal metastases Table 2). The parental clones had already accumulated mutations in (Supplementary Fig. 3). Moreover, 22 more mutations were found in all driver genes (KRAS, TP53 and SMAD4) previously shown to drive the liver metastasis. Note that all mutations in the metastatic lesions pancreatic tumorigenesis6. Through combined analysis of high-density were clonal, that is, present in the great majority if not all neoplastic single nucleotide polymorphism (SNP) chip data on the index lesion cells of the metastasis, as assessed by Sanger sequencing. Thus, these (Supplementary Table 3) plus the sequencing data on all lesions mutations were present in the cell that clonally expanded to become (Supplementary Table 2) we found that the vast majority of homo- the metastasis. Similarly, large numbers of progressor mutations were zygous mutations (51 mutations, representing 89% of all homozygous generally observed in the metastases from each of the seven cases mutations) in the index lesion were already present in the parental examined (Fig. 2 and Supplementary Figs 3–8). clones. Homozygous mutations are characteristic of tumour suppressor To distinguish between the possibilities that clonal evolution genes such as SMAD4 and CDKN2A and often occur in association with occurred inside the primary cancer versus within secondary sites, we chromosomal instability7. In sum, the parental clones harboured the sectioned the primary tumours from two patients into numerous, three- majority of deleterious genetic alterations and chromosomal instability, dimensionally organized pieces (Fig. 2a, b) and examined the DNA Slice number Slice 1 Slice 2 Slice 3 a 15432 b Y U B W T R V S Q G S D F A C E 3 cm RL Slice 4 I Slice 5 K Superior X P O J Right Left 5 mm NL Pancreatic tail Inferior H I M Necrosis Normal Parental c Pa08 C13orf22 Parental clone GPC2 GRM8 AKAP12 HPCAL1 ODZ4 C1RL MLL2 CCNB3 ATP2B3 ITPR1 OR4A16 B3GALT1 NEB CNGB3 PALMD BCL2A1 JPH4 OR5J2 LRRTM4 NP_001074311.1 CTNND2 RAD9B U CCNYL3 KAL1 OR8H1 SESN2 DICER1 LOC167127 MRGX1 NCL CGN C20orf26 P SYNE1
Recommended publications
  • Genetic Variation Across the Human Olfactory Receptor Repertoire Alters Odor Perception
    bioRxiv preprint doi: https://doi.org/10.1101/212431; this version posted November 1, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Genetic variation across the human olfactory receptor repertoire alters odor perception Casey Trimmer1,*, Andreas Keller2, Nicolle R. Murphy1, Lindsey L. Snyder1, Jason R. Willer3, Maira Nagai4,5, Nicholas Katsanis3, Leslie B. Vosshall2,6,7, Hiroaki Matsunami4,8, and Joel D. Mainland1,9 1Monell Chemical Senses Center, Philadelphia, Pennsylvania, USA 2Laboratory of Neurogenetics and Behavior, The Rockefeller University, New York, New York, USA 3Center for Human Disease Modeling, Duke University Medical Center, Durham, North Carolina, USA 4Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA 5Department of Biochemistry, University of Sao Paulo, Sao Paulo, Brazil 6Howard Hughes Medical Institute, New York, New York, USA 7Kavli Neural Systems Institute, New York, New York, USA 8Department of Neurobiology and Duke Institute for Brain Sciences, Duke University Medical Center, Durham, North Carolina, USA 9Department of Neuroscience, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA *[email protected] ABSTRACT The human olfactory receptor repertoire is characterized by an abundance of genetic variation that affects receptor response, but the perceptual effects of this variation are unclear. To address this issue, we sequenced the OR repertoire in 332 individuals and examined the relationship between genetic variation and 276 olfactory phenotypes, including the perceived intensity and pleasantness of 68 odorants at two concentrations, detection thresholds of three odorants, and general olfactory acuity.
    [Show full text]
  • Genomic Correlates of Relationship QTL Involved in Fore- Versus Hind Limb Divergence in Mice
    Loyola University Chicago Loyola eCommons Biology: Faculty Publications and Other Works Faculty Publications 2013 Genomic Correlates of Relationship QTL Involved in Fore- Versus Hind Limb Divergence in Mice Mihaela Palicev Gunter P. Wagner James P. Noonan Benedikt Hallgrimsson James M. Cheverud Loyola University Chicago, [email protected] Follow this and additional works at: https://ecommons.luc.edu/biology_facpubs Part of the Biology Commons Recommended Citation Palicev, M, GP Wagner, JP Noonan, B Hallgrimsson, and JM Cheverud. "Genomic Correlates of Relationship QTL Involved in Fore- Versus Hind Limb Divergence in Mice." Genome Biology and Evolution 5(10), 2013. This Article is brought to you for free and open access by the Faculty Publications at Loyola eCommons. It has been accepted for inclusion in Biology: Faculty Publications and Other Works by an authorized administrator of Loyola eCommons. For more information, please contact [email protected]. This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License. © Palicev et al., 2013. GBE Genomic Correlates of Relationship QTL Involved in Fore- versus Hind Limb Divergence in Mice Mihaela Pavlicev1,2,*, Gu¨ nter P. Wagner3, James P. Noonan4, Benedikt Hallgrı´msson5,and James M. Cheverud6 1Konrad Lorenz Institute for Evolution and Cognition Research, Altenberg, Austria 2Department of Pediatrics, Cincinnati Children‘s Hospital Medical Center, Cincinnati, Ohio 3Yale Systems Biology Institute and Department of Ecology and Evolutionary Biology, Yale University 4Department of Genetics, Yale University School of Medicine 5Department of Cell Biology and Anatomy, The McCaig Institute for Bone and Joint Health and the Alberta Children’s Hospital Research Institute for Child and Maternal Health, University of Calgary, Calgary, Canada 6Department of Anatomy and Neurobiology, Washington University *Corresponding author: E-mail: [email protected].
    [Show full text]
  • Primepcr™Assay Validation Report
    PrimePCR™Assay Validation Report Gene Information Gene Name olfactory receptor, family 5, subfamily J, member 2 Gene Symbol OR5J2 Organism Human Gene Summary Olfactory receptors interact with odorant molecules in the nose to initiate a neuronal response that triggers the perception of a smell. The olfactory receptor proteins are members of a large family of G-protein-coupled receptors (GPCR) arising from single coding-exon genes. Olfactory receptors share a 7-transmembrane domain structure with many neurotransmitter and hormone receptors and are responsible for the recognition and G protein-mediated transduction of odorant signals. The olfactory receptor gene family is the largest in the genome. The nomenclature assigned to the olfactory receptor genes and proteins for this organism is independent of other organisms. Gene Aliases OR11-266 RefSeq Accession No. NC_000011.9, NT_167190.1 UniGene ID Hs.537145 Ensembl Gene ID ENSG00000174957 Entrez Gene ID 282775 Assay Information Unique Assay ID qHsaCED0019003 Assay Type SYBR® Green Detected Coding Transcript(s) ENST00000312298 Amplicon Context Sequence CCTTGTTGAGGAATCTGGGCATGATCCTCTTAATCCAAATCACCTCCAAACTCCA CACACCCATGTACTTTTTACTCAGCTGTCTTTCATTTGTGGATGCCTGCTATTCAT CTGCAATT Amplicon Length (bp) 89 Chromosome Location 11:55944206-55944324 Assay Design Exonic Purification Desalted Validation Results Efficiency (%) 104 R2 0.9987 cDNA Cq 29.8 Page 1/5 PrimePCR™Assay Validation Report cDNA Tm (Celsius) 79.5 gDNA Cq 23.17 Specificity (%) 100 Information to assist with data interpretation is provided
    [Show full text]
  • Human Artificial Chromosome (Hac) Vector
    Europäisches Patentamt *EP001559782A1* (19) European Patent Office Office européen des brevets (11) EP 1 559 782 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 158(3) EPC (43) Date of publication: (51) Int Cl.7: C12N 15/09, C12N 1/15, 03.08.2005 Bulletin 2005/31 C12N 1/19, C12N 1/21, C12N 5/10, C12P 21/02 (21) Application number: 03751334.8 (86) International application number: (22) Date of filing: 03.10.2003 PCT/JP2003/012734 (87) International publication number: WO 2004/031385 (15.04.2004 Gazette 2004/16) (84) Designated Contracting States: • KATOH, Motonobu, Tottori University AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Yonago-shi, Tottori 683-8503 (JP) HU IE IT LI LU MC NL PT RO SE SI SK TR • TOMIZUKA, Kazuma, Designated Extension States: Kirin Beer Kabushiki Kaisha AL LT LV MK Takashi-shi, Gunma 370-1295 (JP) • KUROIWA, Yoshimi, (30) Priority: 04.10.2002 JP 2002292853 Kirin Beer Kabushiki Kaisha Takasaki-shi, Gunma 370-1295 (JP) (71) Applicant: KIRIN BEER KABUSHIKI KAISHA • KAKEDA, Minoru, Kirin Beer Kabushiki Kaisha Tokyo 104-8288 (JP) Takasaki-shi, Gunma 370-1295 (JP) (72) Inventors: (74) Representative: HOFFMANN - EITLE • OSHIMURA, Mitsuo, Tottori University Patent- und Rechtsanwälte Yonago-shi, Tottori 683-8503 (JP) Arabellastrasse 4 81925 München (DE) (54) HUMAN ARTIFICIAL CHROMOSOME (HAC) VECTOR (57) The present invention relates to a human arti- ing a cell which expresses foreign DNA. Furthermore, ficial chromosome (HAC) vector and a method for pro- the present invention relates to a method for producing ducing the same.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]
  • Crosstalk in Competing Endogenous RNA Network Reveals the Complex Molecular Mechanism Underlying Lung Cancer
    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 53), pp: 91270-91280 Research Paper Crosstalk in competing endogenous RNA network reveals the complex molecular mechanism underlying lung cancer Xiang Jin1, Yinghui Guan1, Hui Sheng1 and Yang Liu1 1Department of Respiration, The First Hospital of Jilin University, Changchun City, Jilin Province, 130021, China Correspondence to: Yinghui Guan, email: [email protected] Keywords: crosstalk, ceRNA network, lung cancer, molecular mechanism, circRNA-seq Received: March 29, 2017 Accepted: July 16, 2017 Published: August 24, 2017 Copyright: Jin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT We investigated the transcriptional mechanism underlying lung cancer development. RNA sequencing analysis was performed on blood samples from lung cancer cases and healthy controls. Differentially expressed microRNAs (miRNAs), circular RNAs (circRNAs), mRNAs (genes), and long non-coding RNAs (lncRNA) were identified, followed by pathway enrichment analysis. Based on miRNA target interactions, a competing endogenous network was established and significant nodes were screened. Differentially expressed transcriptional factors were retrieved from the TRRUST database and the transcriptional factor regulatory network was constructed. The expression of 59 miRNAs, 18,306 genes,232 lncRNAs, and 292 circRNAs were greatly altered in patients with lung cancer. miRNAs were closely associated with cancer-related pathways, such as pathways in cancer, colorectal cancer, and transcriptional misregulation in cancer. Two novel pathways, olfactory transduction and neuroactive ligand-receptor interactions, were significantly enriched by differentially expressed genes.
    [Show full text]
  • Supplementary Tables Supplemental Table S1: Comparison of the Coverage of Reference Panels Used for SNP Imputation. the Markers
    Supplementary Tables Supplemental Table S1: Comparison of the coverage of reference panels used for SNP imputation. The markers on the Consortium on Asthma among African-ancestry Populations in the Americas (CAAPA) reference panel and Haplotype Reference Consortium (HRG) used to impute SNPs from our AA and CAU participants were compared to one thousand genomes (1kG) dataset. Loci information CAAPA vs 1kG HRC vs 1kG Total loci 45,639,158 90,558,388 Overlapping loci 24,880,301 49,826,569 Percent overlap 54.52% 55.02% 1kG-only loci 9,363,544 15,148,191 Ref-only loci 8,461,186 22,649,501 Supplemental Table S2: SNP imputation results. The total number of SNPs imputed for the AA and CAU participants either using the Michigan imputation server (Minimac) or Beagle. Targets prepared for: AA CAU Beagle 730,616 726,165 Minimac 698,343 660,733 Supplemental Table S3: Allele frequencies of TA2R38 SNPs by each ancestral group and time point. The rs number of each SNP, the location of SNP buy chromosome (CHR) and base pair position (POS) is provided along with the allele frequency (ALLELE:FREQ) for each SNP. Baseline 6-month Baseline 6-month AA (N = 297) AA (N = 234) CAU (N = 198) CAU (N = 151) SNP CHR POS ALLELE:FREQ ALLELE:FREQ ALLELE:FREQ ALLELE:FREQ rs10246939 7 141672604 T:0.49 C:0.51 T:0.50 C:0.50 T:0.54 C:0.46 T:0.54 C:0.46 rs1726866 7 141672705 G:0.68 A:0.32 G:0.68 A:0.32 G:0.46 A:0.54 G:0.46 A:0.54 rs713598 7 141673345 C:0.50 G:0.50 C:0.50 G:0.50 C:0.58 G:0.42 C:0.58 G:0.42 Supplemental Table S4: Linkage disequilibrium analysis of TAS2R38 SNPs at each time point of the intervention.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,347,934 B2 Shekdar Et Al
    USOO9347934B2 (12) United States Patent (10) Patent No.: US 9,347,934 B2 Shekdar et al. (45) Date of Patent: May 24, 2016 (54) ASSAYS FOR IDENTIFYING COMPOUNDS 2008, OO38739 A1 2/2008 Li et al. THAT MODULATE BITTERTASTE 2008/0167286 A1* 7/2008 Gopalakrishnan et al. ........................ 514,21016 (71) Applicants: CHROMOCELL CORPORATION, 2010/01298.33 A1* 5/2010 Brune et al. ................. 435/721 North Brunswick, NJ (US); KRAFT FOODS GROUP BRANDS LLC, FOREIGN PATENT DOCUMENTS Northfield, IL (US) CN 1341632 A 3, 2002 CN 101583717 A 11, 2009 (72) Inventors: Kambiz Shekdar, New York, NY (US); CN 101828.111 A 9, 2010 Purvi Manoj Shah, Bridgewater, NJ WO WO-0038536 A2 7, 2000 WO WO-2004O29087 4/2004 (US); Joseph Gunnet, Flemington, NJ WO WO-2006053771 A2 5, 2006 (US); Jane V. Leland, Wilmette, IL WO WO-2007002026 A2 1/2007 (US); Peter H. Brown, Glenview, IL WO WO-2008057470 5, 2008 (US); Louise Slade, Morris Plains, NJ WO WO-2008119.195 A1 10, 2008 (US) WO WO-20081191.96 10, 2008 WO WO-20081191.97 10, 2008 (73) Assignees: Chromocell Corporation, North W WSi. A2 1929 Brunswick, NJ (US); Kraft Foods WO WO-2010O886.33 8, 2010 Group Brands LLC, Northfield, IL WO WO-2010O99983 A1 9, 2010 (US) WO WO-2013022947 2, 2013 (*) Notice: Subject to any disclaimer, the term of this OTHER PUBLICATIONS patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. Bachmanov et al., Taste Receptor Genes, 2007, 27:389-414.* Behrens et al., Structural Requirements for Bitter Taste Receptor (21) Appl.
    [Show full text]
  • European Patent Office of Opposition to That Patent, in Accordance with the Implementing Regulations
    (19) TZZ Z_T (11) EP 2 884 280 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: G01N 33/566 (2006.01) 09.05.2018 Bulletin 2018/19 (21) Application number: 13197310.9 (22) Date of filing: 15.12.2013 (54) Method for evaluating the scent performance of perfumes and perfume mixtures Verfahren zur Bewertung des Duftverhaltens von Duftstoffen und Duftstoffmischungen Procédé d’evaluation de senteur performance du parfums et mixtures de parfums (84) Designated Contracting States: (56) References cited: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB WO-A2-03/091388 GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR • BAGHAEI KAVEH A: "Deorphanization of human olfactory receptors by luciferase and Ca-imaging (43) Date of publication of application: methods.",METHODS IN MOLECULAR BIOLOGY 17.06.2015 Bulletin 2015/25 (CLIFTON, N.J.) 2013, vol. 1003, 19 June 2013 (2013-06-19), pages229-238, XP008168583, ISSN: (73) Proprietor: Symrise AG 1940-6029 37603 Holzminden (DE) • KAVEH BAGHAEI ET AL: "Olfactory receptors coded by segregating pseudo genes and (72) Inventors: odorants with known specific anosmia.", 33RD • Hatt, Hanns ANNUAL MEETING OF THE ASSOCIATION FOR 44789 Bochum (DE) CHEMORECEPTION, 1 April 2011 (2011-04-01), • Gisselmann, Günter XP055111507, 58456 Witten (DE) • TOUHARA ET AL: "Deorphanizing vertebrate • Ashtibaghaei, Kaveh olfactory receptors: Recent advances in 44801 Bochum (DE) odorant-response assays", NEUROCHEMISTRY • Panten, Johannes INTERNATIONAL, PERGAMON PRESS, 37671 Höxter (DE) OXFORD, GB, vol.
    [Show full text]
  • A Multispecific Investigation of the Metal Effect in Mammalian Odorant
    Chemical Senses, 2018, Vol 00, 1–10 doi:10.1093/chemse/bjy022 Original Article Advance Access Publication Date: 06 April 2018 Original Article A Multispecific Investigation of the Metal Effect in Mammalian Odorant Receptors for Sulfur- Containing Compounds Ruina Zhang1,*, Yi Pan1,*, Lucky Ahmed2, Eric Block3, Yuetian Zhang1, Victor S. Batista2 and Hanyi Zhuang1,4 1Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Shanghai Jiaotong University School of Medicine, 227 South Chongqing Road, Huangpu District, Shanghai 200025, P. R. China, 2Department of Chemistry, Yale University, 225 Prospect Street, New Haven, CT 06520, USA, 3Department of Chemistry, University at Albany, State University of New York, 1400 Washington Avenue Albany, NY 12222, USA and 4Institute of Health Sciences, Shanghai Jiaotong University School of Medicine/Shanghai Institutes for Biological Sciences of Chinese Academy of Sciences, 320 Yueyang Road, Xuhui District, Shanghai 200031, P. R. China *These authors contributed equally to the work. Correspondence to be sent to: Hanyi Zhuang, Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Shanghai Jiaotong University School of Medicine, Shanghai 200025, P. R. China. e-mail: [email protected] and Victor S. Batista, Department of Chemistry, Yale University, New Haven, CT 06520, USA. e-mail: [email protected] Editorial Decision 15 March 2018. Abstract Metal-coordinating compounds are generally known to have strong smells, a phenomenon that can be attributed to the fact that odorant receptors for intense-smelling compounds, such as those containing sulfur, may be metalloproteins. We previously identified a mouse odorant receptor (OR), Olfr1509, that requires copper ions for sensitive detection of a series of metal-coordinating odorants, including (methylthio)methanethiol (MTMT), a strong-smelling component of male mouse urine that attracts female mice.
    [Show full text]
  • The Odorant Receptor OR2W3 on Airway Smooth Muscle Evokes Bronchodilation Via a Cooperative Chemosensory Tradeoff Between TMEM16A and CFTR
    The odorant receptor OR2W3 on airway smooth muscle evokes bronchodilation via a cooperative chemosensory tradeoff between TMEM16A and CFTR Jessie Huanga,1,2, Hong Lama,1, Cynthia Koziol-Whiteb,c, Nathachit Limjunyawongd, Donghwa Kime, Nicholas Kimb, Nikhil Karmacharyac, Premraj Rajkumarf, Danielle Firera, Nicholas M. Dalesiog, Joseph Judec, Richard C. Kurtenh, Jennifer L. Pluznickf, Deepak A. Deshpandei, Raymond B. Penni, Stephen B. Liggette,j, Reynold A. Panettieri Jrc, Xinzhong Dongd,k, and Steven S. Anb,c,2 aDepartment of Environmental Health and Engineering, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205; bDepartment of Pharmacology, Rutgers-Robert Wood Johnson Medical School, The State University of New Jersey, Piscataway, NJ 08854; cRutgers Institute for Translational Medicine and Science, New Brunswick, NJ 08901; dSolomon H. Snyder Department of Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, MD 21205; eCenter for Personalized Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612; fDepartment of Physiology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205; gDepartment of Anesthesiology and Critical Care Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205; hDepartment of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock, AR 72205; iDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Center for Translational Medicine, Jane and Leonard Korman
    [Show full text]